Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: FamiCord AG

Market Cap 66.59M 76.32M 61.38M 57.79M 108M 7.2B 109M 731M 283M 3.55B 286M 280M 12.31B P/E 2026 *
376x
P/E 2027 * 62.7x
Enterprise Value 74.59M 85.49M 68.75M 64.74M 121M 8.07B 122M 819M 317M 3.97B 321M 314M 13.79B EV / Sales 2026 *
0.88x
EV / Sales 2027 * 0.82x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 month 3.5
Extreme 3.4995
3.5
Current year 3.5
Extreme 3.4995
3.5
1 year 3.5
Extreme 3.4995
3.5
3 years 3.5
Extreme 3.4995
3.5
5 years 3.5
Extreme 3.4995
3.5
10 years 3.5
Extreme 3.4995
3.5
Manager TitleAgeSince
Chief Executive Officer 54 2022-03-21
Director of Finance/CFO 53 2024-07-31
Chief Tech/Sci/R&D Officer - 2025-02-28
Director TitleAgeSince
Chairman 62 2017-06-27
Director/Board Member - 2016-12-31
Director/Board Member 53 2021-11-30
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 77.19M
-0.85%+0.31%+46.55%+45.19% 127B
-3.35%+0.49%+0.73%+29.33% 86.11B
+0.69%+4.30%-8.60%+52.01% 25.49B
-1.40%-4.31%+8.97%+40.69% 21.89B
-1.44%-4.77%-1.40%+9.20% 21.28B
+0.05%+1.63%-10.98%-20.81% 20.33B
-3.32%+4.73%+3.05%+120.03% 15.38B
+0.39%-2.32%-5.73%-0.60% 14.4B
-1.27%+4.72%+52.30%+112.98% 13.52B
Average -1.05%+2.25%+9.43%+43.11% 38.32B
Weighted average by Cap. -1.45%+2.07%+18.40%+39.42%

Financials

2026 *2027 *
Net sales 85M 97.42M 78.35M 73.77M 138M 9.19B 139M 933M 362M 4.53B 366M 358M 15.71B 88.4M 101M 81.48M 76.72M 143M 9.56B 144M 970M 376M 4.71B 380M 372M 16.34B
Net income 300K 344K 277K 260K 486K 32.44M 490K 3.29M 1.28M 15.97M 1.29M 1.26M 55.46M 1M 1.15M 922K 868K 1.62M 108M 1.63M 10.98M 4.25M 53.24M 4.3M 4.21M 185M
Net Debt 8M 9.17M 7.37M 6.94M 12.96M 865M 13.07M 87.83M 34.03M 426M 34.42M 33.67M 1.48B 6M 6.88M 5.53M 5.21M 9.72M 649M 9.8M 65.87M 25.52M 319M 25.81M 25.25M 1.11B
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
723
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.760EUR
Average target price
6.500EUR
Spread / Average Target
+72.87%

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!